Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILRB4 STAR-T Cells in Monocytic Leukemia
NCT05739409Phase 1Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- CAR-T Cells, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LILRB4 STAR-T in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Safety and tolerability at 12 months. Started Feb 2023; status: completed.
02
Drugs
LILRB4 STAR-T
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05739409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739409.